Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration
- 1 November 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (11), 3543-3547
- https://doi.org/10.1128/aac.00766-06
Abstract
The objective of the present study was to identify the optimal R207910-containing regimen to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of multidrug-resistant tuberculosis (MDR-TB), concomitant use of antiretroviral drugs, or toxicity. Mice were infected intravenously with 5 × 10 6 CFU of the H37Rv strain and treated five times per week with R207910 alone or various combinations of R207910 with the second-line drugs amikacin (AMK), pyrazinamide (PZA), moxifloxacin (MXF), and ethionamide (ETH). All R207910-containing regimens were significantly more active than the non-R207910-containing regimens after 1 month of therapy. When given for 2 months, R207910 alone was more active than the WHO standard first-line regimen RIF-INH-PZA. When R207910 was combined with second-line drugs, the combinations were more active than the currently recommended regimen of MDR-TB AMK-ETH-MXF-PZA, and culture negativity of both the lungs and spleen was reached after 2 months of treatment in almost every case.Keywords
This publication has 16 references indexed in Scilit:
- In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulceransAntimicrobial Agents and Chemotherapy, 2006
- Bactericidal Activities of R207910 and Other Newer Antimicrobial Agents against Mycobacterium leprae in MiceAntimicrobial Agents and Chemotherapy, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In VivoAntimicrobial Agents and Chemotherapy, 2003
- Gatifloxacin and Ethionamide as the Foundation for Therapy of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant Mycobacterium tuberculosis Infection in BALB/c MiceAntimicrobial Agents and Chemotherapy, 2003
- Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in MiceAntimicrobial Agents and Chemotherapy, 2001
- In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1995
- Therapy of multidrug-resistant tuberculosis: lessons from studies with miceAntimicrobial Agents and Chemotherapy, 1993
- Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experimentsTubercle, 1991